Drug Approval | September 01, 2022
Biological E. announces CDSCO recommendation of its infant’s vaccine
Subject Expert Committee(SEC) of Central Drugs Standard Control Organization (CDSCO)
Subject Expert Committee(SEC) of Central Drugs Standard Control Organization (CDSCO)
The Centre aims at promoting innovation among the scientific community to improve healthcare solutions around the globe
This launch builds upon Hikma’s leading position as one of the largest US providers of nasally administered medicines used for treating seasonal allergies and advances its objective of growing its specialty business in the US
The Phase IV DREAM-CKD trial will enrol 1004 CKD patients in India, including 502 dialysis dependent, 502 dialysis independent CKD patients with anemia.
The existing hospital premises has the scope to further scale up the bed capacity as and when required in the future with minimal Capex.
This industry-academia collaboration will provide students with an opportunity to participate in research activities with multiple international universities and scientists
Complaints to be filed in both United States and Germany alleging that Pfizer and BioNTech's COVID-19 vaccine Comirnaty unlawfully infringes patents Moderna filed between 2010 and 2016
Sandoz is planned to be incorporated in Switzerland and to be listed on the SIX Swiss Exchange, with an American Depositary Receipt (ADR) program in the US
Pending authorization, Moderna ready to ship bivalent booster mRNA-1273.222 in September
It is high time that India assumed a leadership role in healthcare.
Subscribe To Our Newsletter & Stay Updated
